Vnitr Lek 2021, 67(6):368-371 | DOI: 10.36290/vnl.2021.095

Why we still don't achieve blood pressure targets

Vladimír Tuka, Aleš Linhart
2 . interní klinika - klinika kardiologie a angiologie VFN a 1. LF UK, Praha

Arterial hypertension is one of the main modifiable risk factors for atherosclerotic cardiovascular disease. The prevalence of hypertension remains high, and its compensation is still unsatisfactory. In most patients, we should try to achieve office blood pressure values below 140/90 mm Hg, and in those who tolerate treatment well, values around 130/80 mm Hg, as soon as possible, ideally within three months of diagnosis. While lifestyle interventions are essential and should not be overlooked, most hypertensive patients cannot avoid pharmacotherapy, primarily using a combination of two or more antihypertensives. Achieving blood pressure targets, which determine the patient's prognosis, is still not ideal. Factors on both the physician's side and the patient's side contribute to achieving blood pressure targets. The review article offers various approaches to achieving blood pressure targets, such as using fixed combinations.

Keywords: arterial hypertension, fixed combination, therapeutic inertia, treatment adherence, treatment persistence.

Published: October 13, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tuka V, Linhart A. Why we still don't achieve blood pressure targets. Vnitr Lek. 2021;67(6):368-371. doi: 10.36290/vnl.2021.095.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Williams B et al. ESC CardioMed, in Epidemiology and pathophysiology of hypertension. 2020, Oxford University Press.
    2. Yusuf S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case‑control study. Lancet, 2004; 364(9438): 937-952. Go to original source... Go to PubMed...
    3. Lustigová M, Čapková N. Prevalence rizikových faktorů srdečně‑cévních onemocnění v Česku z pohledu demografických charakteristik - vybrané výsledky studie EHES. Demografie, 2017; 59(2): 162-170.
    4. Cífková R et al. 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post‑MONICA, 1985-2016/17. PLoS One, 2020; 15(5): p. e0232845. Go to original source... Go to PubMed...
    5. Kotseva K et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology. 0(0): p. 2047487320908698.
    6. Kotseva K et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2020; 23(6): 636-648. Go to original source... Go to PubMed...
    7. Anand SS et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. European Heart Journal, 2008; 29(7): 932-940. Go to original source... Go to PubMed...
    8. Mnatzaganian G et al. Socioeconomic disparities in the management of coronary heart disease in 438 general practices in Australia. European Journal of Preventive Cardiology. 0(0): p. 2047487320912087.
    9. Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta‑analysis. Lancet, 2016; 387(10022): 957-967. Go to original source... Go to PubMed...
    10. Böhm M et al. Achieved blood pressure and cardiovascular outcomes in high‑risk patients: results from ONTARGET and TRANSCEND trials. Lancet, 2017; 389(10085): 2226-2237. Go to original source... Go to PubMed...
    11. Williams B et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, 2018; 39(33): 3021-3104. Go to original source... Go to PubMed...
    12. Hanssen H et al. Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. European Journal of Preventive Cardiology, 2021. Go to original source... Go to PubMed...
    13. Kjeldsen SE et al. Physician (investigator) inertia in apparent treatment‑resistant hypertension - Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. Blood Pressure, 2015; 24(1): 1-6. Go to original source... Go to PubMed...
    14. Lebeau JP et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract, 2014; 15: p. 130. Go to original source... Go to PubMed...
    15. Souček M. Adherence a perzistence se zaměřením na léčbu hypertenzních pacientů. Vnitřní lékařství, 2013; 59(6): 482-485. Go to PubMed...
    16. Tuka V jr, Tuka V. Jak motivovat pacienta ke změně životního stylu? Vnitřní lékařství, 2020; 66(1): 60-61.
    17. Vrijens B et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Bmj, 2008; 336(7653): 1114-1117. Go to original source... Go to PubMed...
    18. Jamerson K et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high‑risk patients. N Engl J Med, 2008; 359(23): 2417-2428. Go to original source... Go to PubMed...
    19. Widimský J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství, 2018; 64(7): 771-796.
    20. Gradman AH et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension, 2013; 61(2): 309-318. Go to original source... Go to PubMed...
    21. Simons LA. Long‑term persistence with single‑pill, fixed‑dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017 Oct; 33(10): 1783-1787. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.